A review of public information. No hands-on testing, laboratory inspection or medical review is claimed.
The current displayed promotion
The rendered pricing page displayed semaglutide from $99 per month and tirzepatide from $198 on October 9. The semaglutide card attached annual-plan language and code FOREVER12; the tirzepatide card showed FOREVER500. These figures differ from older page extracts, so our records preserve the checked promotion and its unresolved checkout terms.
Sources: Fridays — current plans, FDA — concerns with unapproved GLP-1 drugs, FDA — compounding questions and answers
Included care is useful, but commitment remains
The signature plans advertise medication, coaching, provider visits and no separate membership fee. That is different from a medicine-only manufacturer price. The page’s lowest monthly display does not by itself establish how much is collected today, whether all strengths qualify, or what happens when treatment changes before the planned term ends.
Sources: Fridays — current plans, FDA — concerns with unapproved GLP-1 drugs, FDA — compounding questions and answers
Brand-name plans are another purchase
The page also advertises branded medicines and a care membership for Wegovy options. It describes $49 for the first membership month and an ongoing figure as low as $98 with an annual prepayment; medication is excluded for those Wegovy membership offers. These must not be merged with the compounded-plan headline or treated as a universal Wegovy price.
Sources: Fridays — current plans, FDA — concerns with unapproved GLP-1 drugs, FDA — compounding questions and answers
Our assessment
Fridays offers a useful care-included comparison if the exact promotion and payment term suit the patient. Request the full commitment, renewal, dose coverage and refund conditions before budgeting from the headline. Its page defines a displayed success rate in terms of order fulfillment and delivery, not a verified clinical weight-loss result; we do not use it as a treatment score.
Sources: Fridays — current plans, FDA — concerns with unapproved GLP-1 drugs, FDA — compounding questions and answers
Every offer in our file.
Compounded semaglutide promotion
Compounded prescriptionRendered promotional card from $99/month with annual-plan language and code FOREVER12. Medication and signature-plan care are advertised as included. Confirm the actual initial charge and eligibility.
Compounded tirzepatide promotion
Compounded prescriptionRendered promotional card from $198/month with annual-plan language and code FOREVER500. Medication and signature-plan care are advertised as included. Confirm the actual initial charge and eligibility.
Follow the evidence
Sources & price notes
Each source retains its own check date. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- Fridays — current plans ↗
Rendered October 9: semaglutide from $99/month with annual-plan language and code FOREVER12; tirzepatide from $198 with code FOREVER500. Initial charge and full promotional conditions need confirmation.
Checked October 9, 2026
- FDA — concerns with unapproved GLP-1 drugs ↗
Safety, dosing errors, salt forms and misleading online marketing. Regulatory page rechecked October 9, 2026; retain distinctions between approval, risk information and compounding nominations.
Checked October 9, 2026
- FDA — compounding questions and answers ↗
Clinical and regulatory context. A compounded preparation is not FDA-approved.
Checked October 8, 2026